Monitor for initiation of the Phase 2b/3 trial as a near-term catalyst; while the insider buy signals confidence, it is small in magnitude and not yet a fundamental shift.
Price Chart
Executive Summary
OKYO Pharma announced that Non-Executive Director John Brancaccio purchased 5,000 additional shares at $1.61, increasing his total holding to 31,201 shares. The company also highlighted recent positive Phase 2a trial results for its drug urcosimod in treating neuropathic corneal pain and reiterated plans to launch a Phase 2b/3 trial in the first half of 2026.
Key Facts
- Non-Executive Director John Brancaccio acquired 5,000 OKYO shares at $1.61 per share.
- His total ownership is now 31,201 ordinary shares.
- Urcosimod showed positive pain reduction results in a Phase 2a NCP trial with 18 subjects.
- A prior Phase 2 trial in dry eye disease (240 subjects) also showed significant pain reduction.
- OKYO plans to initiate a ~150-patient Phase 2b/3 trial for urcosimod in NCP in the first half of 2026.
Financial Impact
Insider purchase of $8,050 (5,000 shares at $1.61) — immaterial to market cap of $55M.
Risk Factors
- Clinical-stage biotech with no approved products; high development risk.
- Phase 2a trial was very small (18 subjects), limiting statistical power.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259176 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers